CA2704290C - Method for promoting angiogenesis, vascularization or vessel repair or for inhibiting tumor angiogenesis - Google Patents

Method for promoting angiogenesis, vascularization or vessel repair or for inhibiting tumor angiogenesis Download PDF

Info

Publication number
CA2704290C
CA2704290C CA2704290A CA2704290A CA2704290C CA 2704290 C CA2704290 C CA 2704290C CA 2704290 A CA2704290 A CA 2704290A CA 2704290 A CA2704290 A CA 2704290A CA 2704290 C CA2704290 C CA 2704290C
Authority
CA
Canada
Prior art keywords
mir
antisense molecule
cell
angiogenesis
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2704290A
Other languages
English (en)
French (fr)
Other versions
CA2704290A1 (en
Inventor
Stefanie Dimmeler
Andreas M. Zeiher
Angelika Bonauer
Carmen Urbich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe University Frankfurt
Original Assignee
T2cure GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T2cure GmbH filed Critical T2cure GmbH
Publication of CA2704290A1 publication Critical patent/CA2704290A1/en
Application granted granted Critical
Publication of CA2704290C publication Critical patent/CA2704290C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2704290A 2007-10-30 2008-10-30 Method for promoting angiogenesis, vascularization or vessel repair or for inhibiting tumor angiogenesis Expired - Fee Related CA2704290C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007052114A DE102007052114B4 (de) 2007-10-30 2007-10-30 Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
DE102007052114.8 2007-10-30
PCT/DE2008/001759 WO2009056116A1 (de) 2007-10-30 2008-10-30 Verfahren zur förderung der angiogenese, vaskularisierung oder gefässreparatur oder zur hemmung der tumorangiogenese

Publications (2)

Publication Number Publication Date
CA2704290A1 CA2704290A1 (en) 2009-05-07
CA2704290C true CA2704290C (en) 2018-05-15

Family

ID=40375407

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2704290A Expired - Fee Related CA2704290C (en) 2007-10-30 2008-10-30 Method for promoting angiogenesis, vascularization or vessel repair or for inhibiting tumor angiogenesis

Country Status (16)

Country Link
US (4) US8258113B2 (enExample)
EP (3) EP2217704B1 (enExample)
JP (4) JP5898843B2 (enExample)
CA (1) CA2704290C (enExample)
CY (2) CY1120360T1 (enExample)
DE (1) DE102007052114B4 (enExample)
DK (2) DK2684955T3 (enExample)
ES (2) ES2618203T3 (enExample)
HR (2) HRP20170346T1 (enExample)
HU (2) HUE037494T2 (enExample)
LT (2) LT2684955T (enExample)
NO (1) NO2684955T3 (enExample)
PL (2) PL2684955T3 (enExample)
PT (2) PT2684955T (enExample)
SI (2) SI2684955T1 (enExample)
WO (1) WO2009056116A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
JP2010500011A (ja) 2006-08-08 2010-01-07 ガンサー ハートマン ５’リン酸オリゴヌクレオチドの構造および使用
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US20130302293A1 (en) * 2010-11-11 2013-11-14 Keith A. Webster Compositions, cells, kits and methods for autologous stem cell therapy
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
ES2606636T3 (es) * 2013-01-24 2017-03-24 Pierre Fabre Médicament S.A.S. Composición que comprende un antagomir encapsulado
MX364814B (es) 2013-03-15 2019-05-08 Miragen Therapeutics Inc Nucleosidos biciclicos unidos en puente.
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US20160122762A1 (en) * 2014-10-27 2016-05-05 University Of Iowa Research Foundation Methods of treating atherosclerosis
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
CN107586784B (zh) * 2016-07-08 2020-08-25 田小利 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3612191B1 (en) 2017-04-19 2026-03-11 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
US11674141B2 (en) * 2018-02-28 2023-06-13 National University Corporation Tokyo Medical And Dental University Ischemic-lesion-site-specific gene therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
EP2471924A1 (en) * 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
US20090209621A1 (en) * 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
ES2425387T3 (es) * 2006-07-13 2013-10-15 The Ohio State University Research Foundation Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
US8466117B2 (en) * 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008070082A2 (en) * 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2009004632A2 (en) * 2007-07-05 2009-01-08 Yeda Research And Development Co. Ltd. Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
BRPI0813527A2 (pt) * 2007-07-18 2014-12-30 Univ Colorado Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Also Published As

Publication number Publication date
PT2684955T (pt) 2017-12-13
HUE037494T2 (hu) 2018-08-28
HRP20171874T1 (hr) 2018-01-12
PL2217704T3 (pl) 2017-06-30
US8912158B2 (en) 2014-12-16
NO2684955T3 (enExample) 2018-02-03
HUE031559T2 (hu) 2017-07-28
JP2018083817A (ja) 2018-05-31
PL2684955T3 (pl) 2018-05-30
PT2217704T (pt) 2017-03-15
EP2217704B1 (de) 2016-12-07
LT2684955T (lt) 2017-12-27
DK2217704T3 (en) 2017-03-13
JP5898843B2 (ja) 2016-04-06
US8258113B2 (en) 2012-09-04
HRP20170346T1 (hr) 2017-04-21
LT2217704T (lt) 2017-04-10
JP2014196317A (ja) 2014-10-16
DE102007052114B4 (de) 2011-01-05
EP2217704A1 (de) 2010-08-18
EP2684955A1 (de) 2014-01-15
US20150018407A1 (en) 2015-01-15
US20120322856A1 (en) 2012-12-20
ES2651287T3 (es) 2018-01-25
WO2009056116A1 (de) 2009-05-07
JP2016199565A (ja) 2016-12-01
EP2684955B1 (de) 2017-09-06
EP2684956A1 (de) 2014-01-15
CY1120226T1 (el) 2018-12-12
US9279123B2 (en) 2016-03-08
ES2618203T3 (es) 2017-06-21
DK2684955T3 (en) 2017-12-18
JP2011500858A (ja) 2011-01-06
US20160237433A1 (en) 2016-08-18
US9862949B2 (en) 2018-01-09
CY1120360T1 (el) 2019-07-10
SI2684955T1 (en) 2018-01-31
DE102007052114A1 (de) 2009-05-07
CA2704290A1 (en) 2009-05-07
US20100324118A1 (en) 2010-12-23
SI2217704T1 (sl) 2017-05-31
EP2684956B1 (de) 2017-08-23

Similar Documents

Publication Publication Date Title
US9862949B2 (en) Method for the inhibition of angiogenesis
US8691783B2 (en) MicroRNA-24
EP2504434B1 (en) Pharmaceutical composition comprising mirna-100 and its use in the modulation of blood vessel growth and endothelial inflammation
US20240110156A1 (en) Cardiogenic mesoderm formation regulators
US9051568B2 (en) Anti-sense microrna expression vectors
Behbahani The role of MicroRNAs in endothelial progenitor cell function
HK1193843B (en) Method for promoting angiogenesis, vascularisation or vessel repair or for inhibiting tumour angiogenesis
Cicchillitti et al. Valeria Ambrosino3, Annalisa Antonini2, Maurizio C. Capogrossi2, Carlo Gaetano4, Giulia Piaggio3, and Fabio Martelli1
HK1193844A (en) Methods for promoting angiogenesis, vascularisation or vessel repair or for inhibiting tumour angiogenesis
HK1193843A (en) Method for promoting angiogenesis, vascularisation or vessel repair or for inhibiting tumour angiogenesis
Rohde Aptamer-mediated transport of microRNAs into cells of the cardiovascular system
US20180214475A1 (en) microRNAS FOR THE TREATMENT OF HEART DISEASES

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131030

MKLA Lapsed

Effective date: 20221031